Breast cancer drug repurposed for cystic fibrosis in groundbreaking trial

This study is testing whether tamoxifen, a drug used for breast cancer, is safe and tolerable for adults with cystic fibrosis who have genetic mutations that make them ineligible for current targeted CFTR modulator drugs. Thirty-five participants will take tamoxifen daily for six months, with regular clinic visits for checkups and tests. The research aims to see if tamoxifen can help control the disease by activating an alternative chloride channel in the lungs, potentially improving lung function and quality of life.